During the past decade, CHU de Saint Etienne conducted 41 clinical trials. In the 10-year time frame, 41 clinical trials started and 9 clinical trials were completed, i.e. on average, 22% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 9 clinical trials were completed. i.e. 45% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU de Saint Etienne" #1 sponsor was "Centre Hospitalier Universitaire de Saint Etienne" with 6 trials, followed by "Eli Lilly and Company" with 5 trials sponsored, "Actelion" with 3 trials sponsored, "Janssen Research & Development, LLC" with 3 trials sponsored and "Centre Hospitalier Universitaire de Nīmes" with 3 trials sponsored. Other sponsors include 26 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU de Saint Etienne" #1 collaborator was "Institut de Cancérologie de la Loire" with 3 trials as a collaborator, "Ministry of Health, France" with 2 trials as a collaborator, "Takeda Development Center Americas, Inc." with 2 trials as a collaborator, "Acute Leukemia French Association" with 1 trials as a collaborator and "BPIfrance" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "CHU de Saint Etienne" are "Ulcerative Colitis" (4 trials), "Crohn Disease" (3 trials), "Crohn's Disease" (3 trials), "Acute Myeloid Leukemia" (2 trials) and "Chronic Thromboembolic Pulmonary Hypertension" (2 trials). Many other conditions were trialed in "CHU de Saint Etienne" in a lesser frequency.

Most popular intervention types in "CHU de Saint Etienne" are "Drug" (28 trials), "Other" (11 trials), "Biological" (6 trials), "Device" (3 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Ustekinumab" (4 trials), "Data collection" (2 trials), "Galcanezumab" (2 trials) and "Mirikizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "CHU de Saint Etienne" are 48 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are 23 active trials in "CHU de Saint Etienne". 2 are not yet recruiting, 17 are recruiting, 3 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 19 completed trials in CHU de Saint Etienne, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in CHU de Saint Etienne, 0 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 5 trials that are defined as “Not Applicable".